Human Health Biotechnologies to 2015:
This article provides an overview of the current use of biotechnology to produce human health products and short-term estimates of the number and types of these products that are likely to reach the market by 2015. Relevant health products include biopharmaceuticals, experimental therapies (e.g. cel...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , |
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Paris
OECD Publishing
2010
|
| Subjects: | |
| Online Access: | DE-384 DE-473 DE-824 DE-29 DE-739 DE-355 DE-20 DE-1028 DE-1049 DE-521 DE-861 DE-898 DE-92 DE-91 DE-573 DE-19 Volltext |
| Summary: | This article provides an overview of the current use of biotechnology to produce human health products and short-term estimates of the number and types of these products that are likely to reach the market by 2015. Relevant health products include biopharmaceuticals, experimental therapies (e.g. cell/tissue engineering and gene therapy), small molecule therapeutics, diagnostics, bioinformatics (including DNA sequencing and pharmacogenetics), functional food and nutraceuticals, and medical devices. The analysis of current use is based on regulatory approval data and the current literature and includes a comparison of the additional therapeutic value of biopharmaceuticals compared to small molecule pharmaceuticals. The short-term estimates of the number and types of products that are likely to reach the market by 2015 are based, where possible, on an analysis of quantitative data on clinical trials. For several other products, including functional foods and nutraceuticals, it is not possible to make short-term estimates due to a lack of reliable data. While the biopharmaceutical share of all pharmaceuticals reaching the market is expected to remain very close to historical levels, biotechnology is expected to be used in the discovery, development, manufacturing, and/or prescribing of nearly all new drugs by 2015. In addition, the use of biotech based diagnostics (especially genetic testing), bioinformatics, and pharmacogenetics is likely to increase. In some cases, these technologies will be used to improve the safety and efficacy of clinical trials, to personalise prescribing practises, and to reduce adverse drug reactions |
| Physical Description: | 1 Online-Ressource (95 Seiten) 19 x 27cm |
| DOI: | 10.1787/gen_papers-2009-5kmjkjtfxdg7 |
Staff View
MARC
| LEADER | 00000nma a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV047939566 | ||
| 003 | DE-604 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 220413s2010 |||| o||u| ||||||eng d | ||
| 024 | 7 | |a 10.1787/gen_papers-2009-5kmjkjtfxdg7 |2 doi | |
| 035 | |a (ZDB-13-SOC)061267899 | ||
| 035 | |a (OCoLC)961384080 | ||
| 035 | |a (DE-599)BVBBV047939566 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-384 |a DE-91 |a DE-473 |a DE-824 |a DE-29 |a DE-739 |a DE-355 |a DE-20 |a DE-1028 |a DE-1049 |a DE-188 |a DE-521 |a DE-861 |a DE-898 |a DE-92 |a DE-573 |a DE-19 | ||
| 100 | 1 | |a Arundel, Anthony |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Human Health Biotechnologies to 2015 |c Anthony Arundel, David Sawaya and Ioana Valeanu |
| 264 | 1 | |a Paris |b OECD Publishing |c 2010 | |
| 300 | |a 1 Online-Ressource (95 Seiten) |c 19 x 27cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 520 | |a This article provides an overview of the current use of biotechnology to produce human health products and short-term estimates of the number and types of these products that are likely to reach the market by 2015. Relevant health products include biopharmaceuticals, experimental therapies (e.g. cell/tissue engineering and gene therapy), small molecule therapeutics, diagnostics, bioinformatics (including DNA sequencing and pharmacogenetics), functional food and nutraceuticals, and medical devices. The analysis of current use is based on regulatory approval data and the current literature and includes a comparison of the additional therapeutic value of biopharmaceuticals compared to small molecule pharmaceuticals. The short-term estimates of the number and types of products that are likely to reach the market by 2015 are based, where possible, on an analysis of quantitative data on clinical trials. For several other products, including functional foods and nutraceuticals, it is not possible to make short-term estimates due to a lack of reliable data. While the biopharmaceutical share of all pharmaceuticals reaching the market is expected to remain very close to historical levels, biotechnology is expected to be used in the discovery, development, manufacturing, and/or prescribing of nearly all new drugs by 2015. In addition, the use of biotech based diagnostics (especially genetic testing), bioinformatics, and pharmacogenetics is likely to increase. In some cases, these technologies will be used to improve the safety and efficacy of clinical trials, to personalise prescribing practises, and to reduce adverse drug reactions | ||
| 650 | 4 | |a Economics | |
| 700 | 1 | |a Sawaya, David |4 ctb | |
| 700 | 1 | |a Valeanu, Ioana |4 ctb | |
| 856 | 4 | 0 | |u https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ebook | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-033321060 | |
| 966 | e | |u https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |l DE-384 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |l DE-473 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |l DE-824 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |l DE-29 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |l DE-739 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |l DE-355 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |l DE-20 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |l DE-1028 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |l DE-1049 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |l DE-521 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |l DE-861 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |l DE-898 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |l DE-92 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |l DE-91 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |l DE-573 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |l DE-19 |p ZDB-13-SOC |x Verlag |3 Volltext | |
Record in the Search Index
| _version_ | 1815091529781346304 |
|---|---|
| adam_text | |
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Arundel, Anthony |
| author2 | Sawaya, David Valeanu, Ioana |
| author2_role | ctb ctb |
| author2_variant | d s ds i v iv |
| author_facet | Arundel, Anthony Sawaya, David Valeanu, Ioana |
| author_role | aut |
| author_sort | Arundel, Anthony |
| author_variant | a a aa |
| building | Verbundindex |
| bvnumber | BV047939566 |
| collection | ebook |
| ctrlnum | (ZDB-13-SOC)061267899 (OCoLC)961384080 (DE-599)BVBBV047939566 |
| discipline | Wirtschaftswissenschaften |
| discipline_str_mv | Wirtschaftswissenschaften |
| doi_str_mv | 10.1787/gen_papers-2009-5kmjkjtfxdg7 |
| format | Electronic Book Chapter |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nma a2200000zc 4500</leader><controlfield tag="001">BV047939566</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">220413s2010 |||| o||u| ||||||eng d</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-13-SOC)061267899</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)961384080</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV047939566</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-384</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-1028</subfield><subfield code="a">DE-1049</subfield><subfield code="a">DE-188</subfield><subfield code="a">DE-521</subfield><subfield code="a">DE-861</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-92</subfield><subfield code="a">DE-573</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Arundel, Anthony</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Human Health Biotechnologies to 2015</subfield><subfield code="c">Anthony Arundel, David Sawaya and Ioana Valeanu</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2010</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (95 Seiten)</subfield><subfield code="c">19 x 27cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This article provides an overview of the current use of biotechnology to produce human health products and short-term estimates of the number and types of these products that are likely to reach the market by 2015. Relevant health products include biopharmaceuticals, experimental therapies (e.g. cell/tissue engineering and gene therapy), small molecule therapeutics, diagnostics, bioinformatics (including DNA sequencing and pharmacogenetics), functional food and nutraceuticals, and medical devices. The analysis of current use is based on regulatory approval data and the current literature and includes a comparison of the additional therapeutic value of biopharmaceuticals compared to small molecule pharmaceuticals. The short-term estimates of the number and types of products that are likely to reach the market by 2015 are based, where possible, on an analysis of quantitative data on clinical trials. For several other products, including functional foods and nutraceuticals, it is not possible to make short-term estimates due to a lack of reliable data. While the biopharmaceutical share of all pharmaceuticals reaching the market is expected to remain very close to historical levels, biotechnology is expected to be used in the discovery, development, manufacturing, and/or prescribing of nearly all new drugs by 2015. In addition, the use of biotech based diagnostics (especially genetic testing), bioinformatics, and pharmacogenetics is likely to increase. In some cases, these technologies will be used to improve the safety and efficacy of clinical trials, to personalise prescribing practises, and to reduce adverse drug reactions</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Economics</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sawaya, David</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Valeanu, Ioana</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ebook</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033321060</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="l">DE-384</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="l">DE-473</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="l">DE-824</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="l">DE-29</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="l">DE-739</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="l">DE-355</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="l">DE-20</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="l">DE-1028</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="l">DE-1049</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="l">DE-521</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="l">DE-861</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="l">DE-898</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="l">DE-92</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="l">DE-91</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="l">DE-573</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7</subfield><subfield code="l">DE-19</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV047939566 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T19:35:10Z |
| indexdate | 2024-11-07T19:02:53Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033321060 |
| oclc_num | 961384080 |
| open_access_boolean | |
| owner | DE-384 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-824 DE-29 DE-739 DE-355 DE-BY-UBR DE-20 DE-1028 DE-1049 DE-188 DE-521 DE-861 DE-898 DE-BY-UBR DE-92 DE-573 DE-19 DE-BY-UBM |
| owner_facet | DE-384 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-824 DE-29 DE-739 DE-355 DE-BY-UBR DE-20 DE-1028 DE-1049 DE-188 DE-521 DE-861 DE-898 DE-BY-UBR DE-92 DE-573 DE-19 DE-BY-UBM |
| physical | 1 Online-Ressource (95 Seiten) 19 x 27cm |
| psigel | ebook ZDB-13-SOC |
| publishDate | 2010 |
| publishDateSearch | 2010 |
| publishDateSort | 2010 |
| publisher | OECD Publishing |
| record_format | marc |
| spelling | Arundel, Anthony Verfasser aut Human Health Biotechnologies to 2015 Anthony Arundel, David Sawaya and Ioana Valeanu Paris OECD Publishing 2010 1 Online-Ressource (95 Seiten) 19 x 27cm txt rdacontent c rdamedia cr rdacarrier This article provides an overview of the current use of biotechnology to produce human health products and short-term estimates of the number and types of these products that are likely to reach the market by 2015. Relevant health products include biopharmaceuticals, experimental therapies (e.g. cell/tissue engineering and gene therapy), small molecule therapeutics, diagnostics, bioinformatics (including DNA sequencing and pharmacogenetics), functional food and nutraceuticals, and medical devices. The analysis of current use is based on regulatory approval data and the current literature and includes a comparison of the additional therapeutic value of biopharmaceuticals compared to small molecule pharmaceuticals. The short-term estimates of the number and types of products that are likely to reach the market by 2015 are based, where possible, on an analysis of quantitative data on clinical trials. For several other products, including functional foods and nutraceuticals, it is not possible to make short-term estimates due to a lack of reliable data. While the biopharmaceutical share of all pharmaceuticals reaching the market is expected to remain very close to historical levels, biotechnology is expected to be used in the discovery, development, manufacturing, and/or prescribing of nearly all new drugs by 2015. In addition, the use of biotech based diagnostics (especially genetic testing), bioinformatics, and pharmacogenetics is likely to increase. In some cases, these technologies will be used to improve the safety and efficacy of clinical trials, to personalise prescribing practises, and to reduce adverse drug reactions Economics Sawaya, David ctb Valeanu, Ioana ctb https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Arundel, Anthony Human Health Biotechnologies to 2015 Economics |
| title | Human Health Biotechnologies to 2015 |
| title_auth | Human Health Biotechnologies to 2015 |
| title_exact_search | Human Health Biotechnologies to 2015 |
| title_exact_search_txtP | Human Health Biotechnologies to 2015 |
| title_full | Human Health Biotechnologies to 2015 Anthony Arundel, David Sawaya and Ioana Valeanu |
| title_fullStr | Human Health Biotechnologies to 2015 Anthony Arundel, David Sawaya and Ioana Valeanu |
| title_full_unstemmed | Human Health Biotechnologies to 2015 Anthony Arundel, David Sawaya and Ioana Valeanu |
| title_short | Human Health Biotechnologies to 2015 |
| title_sort | human health biotechnologies to 2015 |
| topic | Economics |
| topic_facet | Economics |
| url | https://doi.org/10.1787/gen_papers-2009-5kmjkjtfxdg7 |
| work_keys_str_mv | AT arundelanthony humanhealthbiotechnologiesto2015 AT sawayadavid humanhealthbiotechnologiesto2015 AT valeanuioana humanhealthbiotechnologiesto2015 |